Management team

• 

  Wu Yusheng

  Chairman / CEO

  National Leading Talent

  PhD from Iowa State University (Organic Chemistry)

  1993- 1996: Postdoctoral research in California Institute of technology

  More than 20 years experience in drug discovery. He worked at Schering-Plough Research Institute from 1996-2009 and led many drug discovery projects for Oncology, Thrombosis, Obesity, Alzheimer, etc. and made key contributions to each of these projects. Thrombosis project was launched in market. Obesity and Alzheimer projects were recommended for the development. Alzheimer project was the first in class in clinic trial and currently in Phase III.

  Founder of TYK Medicines, a leading biotech company in China. His team completed two IND and currently working on more than 10 new drug targets.

  2005: New Jersey Minority Contribution Award.

  2006: President Award of Schering-Plough

  2012: National Leading Talent

  Dr. Wu has published more than 100 SCI papers and more than 50 granted patents in China, US and the European Union.

• 

  Jun Li

  Chief Science Officer

  Over 20+ years’ experience in drug discovery with Bristol-Myers Squibb (1997-2018 ) and Vion Pharm (1996-1997) as principal scientist and project leader, and was directly responsible for the discovery of six clinical drug candidates in the fields of metabolic and cardiovascular diseases, and fibrotic diseases.

  Worked for Chinese Academy of Medical Sciences (1988-1990) as a team leader and found China’s first doping control lab.

  Won First-prize of “(China) State Scientific and Technological Progress Award” and Special-prize of “China Association for Instrumental Analysis Special Award”.

  Twice won Bristol Myers Squibb “Molecular of the Year Award” and Bristol Myers Squibb “Chemistry Leadership Award”.

  Published 40 peer-reviewed articles and holds more than 50+ US/international granted patents.

  BS, University of Science and Technology of China; MS, Chinese Academy of Science; PhD, Iowa State University; Postdoc, Cornell University.

• 

  Xiugui Chen

  VP of the clinical research & development

  MD from Shanghai University of Traditional Chinese Medicine.

  5 years’ attending physician clinical experience; new drug clinical research, development, registration and regulatory experiences over 20 years，focusing on oncology, hepatopathy, digestive and metabolic, and analgesia disease areas.

  Prior to joining TYK Medicines, Chen was the clinical director at Yangtze River Pharmaceuticals responsible for the overall strategy and operations of innovative and generic clinical development programs in all therapeutic areas, and built the clinical medical teams. Prior to that, he had worked at Betta Pharma and Ascletis Pharma, and participated or led the clinical development and registration of anticancer drugs Icotinib, BPI-9016M, BPI-15086 and BPI-2009C, and contributed to the R&D strategy and clinical development of the first HCV new drug Danoprevir in China.

• 

  Mingyu Jiang

  Board Secretary

  China Pharmaceutical University, PhD

  Fordham University, MS in Finance

  Financial Risk Manager(FRM)

  2009-2011 KPMG Huazhen Accounting Firm/Auditor

  2011-2013 KPMG Advisory/Consultant

  2015-2018 Shanghai Pudong Science & Technology Investment Ltd./Risk Manager

  2018-2019 Zheshang Securities Co., Ltd. Research Institute/Senior Analyst

  2019-now TYK medicines Chairman Assistant/Director

  In-charge of several M&A projects in Drug discovery area. Complete financing for biotech at 100 million level.